GSK plc (NYSE:GSK) Declares Quarterly Dividend of $0.39

GSK plc (NYSE:GSK) announced a quarterly dividend on Wednesday, October 30th,Wall Street Journal reports. Shareholders of record on Friday, November 15th will be paid a dividend of 0.3928 per share by the pharmaceutical company on Thursday, January 9th. This represents a $1.57 annualized dividend and a yield of 4.48%. The ex-dividend date is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38.

GSK has decreased its dividend payment by an average of 18.2% per year over the last three years. GSK has a payout ratio of 35.8% meaning its dividend is sufficiently covered by earnings. Equities analysts expect GSK to earn $4.37 per share next year, which means the company should continue to be able to cover its $1.56 annual dividend with an expected future payout ratio of 35.7%.

GSK Trading Down 1.2 %

Shares of NYSE GSK opened at $35.11 on Thursday. The business’s 50 day moving average is $39.46 and its two-hundred day moving average is $40.80. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK has a 1-year low of $34.29 and a 1-year high of $45.92. The stock has a market capitalization of $72.77 billion, a P/E ratio of 22.80, a PEG ratio of 1.36 and a beta of 0.66.

Analysts Set New Price Targets

GSK has been the subject of several recent analyst reports. Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Argus raised shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

Insider Buying and Selling

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.